JP2016527486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527486A5 JP2016527486A5 JP2016519703A JP2016519703A JP2016527486A5 JP 2016527486 A5 JP2016527486 A5 JP 2016527486A5 JP 2016519703 A JP2016519703 A JP 2016519703A JP 2016519703 A JP2016519703 A JP 2016519703A JP 2016527486 A5 JP2016527486 A5 JP 2016527486A5
- Authority
- JP
- Japan
- Prior art keywords
- signature
- change
- difference
- target protein
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 77
- 229940000406 drug candidate Drugs 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 230000000144 pharmacologic effect Effects 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 238000005192 partition Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 2
- 230000009021 linear effect Effects 0.000 claims 9
- 230000009022 nonlinear effect Effects 0.000 claims 5
- 230000003287 optical effect Effects 0.000 claims 3
- HMWAJFNEGAJETK-UHFFFAOYSA-N 1-[6-(dimethylamino)naphthalen-2-yl]prop-2-en-1-one Chemical compound C1=C(C(=O)C=C)C=CC2=CC(N(C)C)=CC=C21 HMWAJFNEGAJETK-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- DENNAQTZCPWYSQ-UHFFFAOYSA-M (2,5-dioxopyrrolidin-1-yl) 3-[[4-[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]pyridin-1-ium-1-yl]methyl]benzoate;bromide Chemical compound [Br-].C1=CC(OC)=CC=C1C1=CN=C(C=2C=C[N+](CC=3C=C(C=CC=3)C(=O)ON3C(CCC3=O)=O)=CC=2)O1 DENNAQTZCPWYSQ-UHFFFAOYSA-M 0.000 claims 1
- ZEIHZWQYRTVVMA-UHFFFAOYSA-N 2-bromo-1-[6-(dimethylamino)naphthalen-2-yl]ethanone Chemical compound C1=C(C(=O)CBr)C=CC2=CC(N(C)C)=CC=C21 ZEIHZWQYRTVVMA-UHFFFAOYSA-N 0.000 claims 1
- CDSULTPOCMWJCM-UHFFFAOYSA-N 4h-chromene-2,3-dione Chemical compound C1=CC=C2OC(=O)C(=O)CC2=C1 CDSULTPOCMWJCM-UHFFFAOYSA-N 0.000 claims 1
- 235000014785 Bergenia crassifolia Nutrition 0.000 claims 1
- 240000004972 Bergenia crassifolia Species 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- WLUHMAZNVINQRC-UHFFFAOYSA-M methanesulfonate;1-[2-[4-[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]pyridin-1-ium-1-yl]ethyl]pyrrole-2,5-dione Chemical compound CS([O-])(=O)=O.C1=CC(OC)=CC=C1C1=CN=C(C=2C=C[N+](CCN3C(C=CC3=O)=O)=CC=2)O1 WLUHMAZNVINQRC-UHFFFAOYSA-M 0.000 claims 1
- 229940126586 small molecule drug Drugs 0.000 claims 1
- 238000005556 structure-activity relationship Methods 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361834782P | 2013-06-13 | 2013-06-13 | |
| US61/834,782 | 2013-06-13 | ||
| PCT/US2014/042428 WO2014201435A1 (en) | 2013-06-13 | 2014-06-13 | Method of screening candidate biochemical entities targeting a target biochemical entity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081077A Division JP2019135498A (ja) | 2013-06-13 | 2019-04-22 | 標的生体実体を標的にする生化学実体候補をスクリーニングする方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527486A JP2016527486A (ja) | 2016-09-08 |
| JP2016527486A5 true JP2016527486A5 (cg-RX-API-DMAC7.html) | 2017-07-27 |
| JP6518656B2 JP6518656B2 (ja) | 2019-05-22 |
Family
ID=52022828
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519703A Active JP6518656B2 (ja) | 2013-06-13 | 2014-06-13 | 標的生体実体を標的にする生化学実体候補をスクリーニングする方法 |
| JP2019081077A Pending JP2019135498A (ja) | 2013-06-13 | 2019-04-22 | 標的生体実体を標的にする生化学実体候補をスクリーニングする方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081077A Pending JP2019135498A (ja) | 2013-06-13 | 2019-04-22 | 標的生体実体を標的にする生化学実体候補をスクリーニングする方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20150330990A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3008465B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6518656B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105659087B (cg-RX-API-DMAC7.html) |
| GB (1) | GB2538216A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014201435A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9182406B2 (en) | 2008-08-04 | 2015-11-10 | Biodesy, Inc. | Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability |
| WO2012129347A1 (en) | 2011-03-21 | 2012-09-27 | Biodesy, Llc | Classification of kinase inhibitors using nonlinear optical techniques |
| GB2520111A (en) | 2012-02-05 | 2015-05-13 | Biodesy Inc | Methods for identifying modulators of Ras using nonlinear techniques |
| US9395358B2 (en) | 2012-02-05 | 2016-07-19 | Biodesy, Inc. | Methods for detecting allosteric modulators of protein |
| US20130288271A1 (en) | 2012-04-25 | 2013-10-31 | Biodesy, Llc | Methods for detecting allosteric modulators of protein |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| GB2531213B (en) * | 2014-06-30 | 2020-09-16 | Biodesy Inc | Systems and methods for high throughput analysis of conformation in biological entities |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| AR102094A1 (es) | 2014-09-25 | 2017-02-01 | Araxes Pharma Llc | Inhibidores de proteínas kras con una mutación g12c |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| EP3237906B8 (en) * | 2014-12-23 | 2020-10-28 | Bluelight Therapeutics, Inc. | Attachment of proteins to interfaces for use in nonlinear optical detection |
| CN107615047A (zh) | 2015-04-02 | 2018-01-19 | 比奥德赛公司 | 利用表面选择性非线性光学技术确定蛋白质结构的方法 |
| MX382355B (es) | 2015-04-10 | 2025-03-13 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos. |
| MX2017013275A (es) | 2015-04-15 | 2018-01-26 | Araxes Pharma Llc | Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos. |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017053567A1 (en) * | 2015-09-22 | 2017-03-30 | Delta Tm Technologies | Designing customized protein-specific buffer systems |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3364977A4 (en) * | 2015-10-19 | 2019-09-04 | Araxes Pharma LLC | PROCESS FOR SCREENING INHIBITORS OF RAS |
| KR20240113606A (ko) | 2015-11-16 | 2024-07-22 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| EP3455628A4 (en) | 2016-05-09 | 2019-12-04 | Biodesy, Inc. | METHOD AND DEVICES FOR DETECTING INTERACTIONS OF PERIPHERAL MEMBRANE PROTEINS USING NONLINEAR OPTICAL TECHNIQUES |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| CN110036010A (zh) | 2016-09-29 | 2019-07-19 | 亚瑞克西斯制药公司 | Kras g12c突变蛋白的抑制剂 |
| CN106650209B (zh) * | 2016-09-30 | 2020-07-07 | 中车南京浦镇车辆有限公司 | 一种车辆应用实时信息确定可靠性增长趋势及参数的方法 |
| JP2019534260A (ja) | 2016-10-07 | 2019-11-28 | アラクセス ファーマ エルエルシー | Ｒａｓの阻害剤としての複素環式化合物およびその使用方法 |
| CN106650317B (zh) * | 2016-10-09 | 2019-04-16 | 南京双运生物技术有限公司 | 一种通过协同过滤公共数据库发现肿瘤潜在基因标靶的方法 |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| EA201992476A1 (ru) * | 2017-04-18 | 2020-02-25 | Икс-Чем, Инк. | Способы идентификации соединений |
| JP2020521740A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体 |
| EP3630745A2 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Covalent inhibitors of kras |
| WO2018218071A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
| US10657525B2 (en) | 2017-06-27 | 2020-05-19 | Kasisto, Inc. | Method and apparatus for determining expense category distance between transactions via transaction signatures |
| WO2020028706A1 (en) | 2018-08-01 | 2020-02-06 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| CA3157710A1 (en) * | 2019-10-15 | 2021-04-22 | Jnana Therapeutics Inc. | Reactive affinity probe-interaction discovery platform |
| CN112630444B (zh) * | 2020-12-11 | 2024-05-24 | 深圳碳云智肽药物科技有限公司 | 基于靶点蛋白的多肽筛选方法 |
| CN113963745A (zh) * | 2021-12-07 | 2022-01-21 | 国际竹藤中心 | 一种构建植物发育分子调控网络的方法及其应用 |
| CN114317669A (zh) * | 2022-01-04 | 2022-04-12 | 北京大学 | 一种基于细胞内蛋白激酶c激活状态筛选药物的方法及高通量筛选装置 |
| WO2024129721A1 (en) * | 2022-12-13 | 2024-06-20 | Lafond David | Systems and methods to predict biological receptor signal response |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2252097A (en) * | 1996-02-01 | 1997-08-22 | Neurocrine Biosciences, Inc. | Methods for increasing endogenous levels of corticotropin-relea sing factor |
| JP2004523726A (ja) * | 2000-07-12 | 2004-08-05 | カロ バイオ ユー エス エイ，インコーポレイテッド | コンフォメーションに敏感な結合ペプチドの同定方法およびその利用 |
| US20020094528A1 (en) * | 2000-11-29 | 2002-07-18 | Salafsky Joshua S. | Method and apparatus using a surface-selective nonlinear optical technique for detection of probe-target interations |
| US20030129649A1 (en) * | 2001-04-24 | 2003-07-10 | Kobilka Brian K. | Conformational assays to detect binding to G protein-coupled receptors |
| US7384773B1 (en) | 2001-05-10 | 2008-06-10 | Pfizer Inc | Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof |
| GB0117326D0 (en) * | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| US20030148391A1 (en) * | 2002-01-24 | 2003-08-07 | Salafsky Joshua S. | Method using a nonlinear optical technique for detection of interactions involving a conformational change |
| US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| US7342093B2 (en) * | 2004-07-23 | 2008-03-11 | University Of Massachusetts | Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins |
| EP1637885A1 (en) | 2004-09-16 | 2006-03-22 | Vivalis | Method of screening by using conformation sensitive peptides |
| WO2006088972A2 (en) * | 2005-02-16 | 2006-08-24 | The General Hospital Corporation | Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism |
| EP1909852A4 (en) * | 2005-06-16 | 2009-02-18 | Univ California | AMYLOID BETA PROTEIN CHANNEL STRUCTURE AND ITS USES FOR THE IDENTIFICATION OF POTENTIAL DRUG MINIMENS FOR NEURODEGENERATIVE ILLNESSES |
| US20090010894A1 (en) * | 2005-12-23 | 2009-01-08 | The Parkinson's Institute | Methods and systems for identifying compounds that modulate alpha-synuclein aggregation |
| AU2007277186B2 (en) * | 2006-07-28 | 2014-01-30 | Presympto, Inc. | Peptide probes for diagnostics and therapeutics |
| WO2010009886A1 (en) * | 2008-07-24 | 2010-01-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Fluorescently or spin-labeled kinases for rapid screening and identification of novel kinase inhibitor scaffolds |
| US9182406B2 (en) | 2008-08-04 | 2015-11-10 | Biodesy, Inc. | Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability |
| WO2010031185A1 (en) * | 2008-09-19 | 2010-03-25 | Protox Therapeutics Inc. | Treating cancer stem cells using targeted cargo proteins |
| WO2012129347A1 (en) * | 2011-03-21 | 2012-09-27 | Biodesy, Llc | Classification of kinase inhibitors using nonlinear optical techniques |
| GB2517857A (en) * | 2012-04-25 | 2015-03-04 | Biodesy Inc | Methods for detecting allosteric modulators of proteins |
-
2014
- 2014-06-13 EP EP14810249.4A patent/EP3008465B1/en active Active
- 2014-06-13 CN CN201480045112.7A patent/CN105659087B/zh active Active
- 2014-06-13 US US14/367,876 patent/US20150330990A1/en not_active Abandoned
- 2014-06-13 GB GB1422724.3A patent/GB2538216A/en not_active Withdrawn
- 2014-06-13 JP JP2016519703A patent/JP6518656B2/ja active Active
- 2014-06-13 WO PCT/US2014/042428 patent/WO2014201435A1/en not_active Ceased
-
2019
- 2019-04-22 JP JP2019081077A patent/JP2019135498A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527486A5 (cg-RX-API-DMAC7.html) | ||
| De Esch et al. | Fragment-to-lead medicinal chemistry publications in 2020 | |
| Putin et al. | Adversarial threshold neural computer for molecular de novo design | |
| Lohr et al. | A small molecule stabilizes the disordered native state of the Alzheimer’s Aβ Peptide | |
| Kramer et al. | The experimental uncertainty of heterogeneous public K i data | |
| Kolossváry et al. | Low mode search. An efficient, automated computational method for conformational analysis: application to cyclic and acyclic alkanes and cyclic peptides | |
| Giannetti et al. | Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors | |
| Chuprina et al. | Drug-and lead-likeness, target class, and molecular diversity analysis of 7.9 million commercially available organic compounds provided by 29 suppliers | |
| Reiher et al. | Trends in hit-to-lead optimization following DNA-encoded library screens | |
| Overman et al. | Raman markers of nonaromatic side chains in an α-helix assembly: Ala, Asp, Glu, Gly, Ile, Leu, Lys, Ser, and Val residues of phage fd subunits | |
| Ritchie et al. | Anti-frameshifting ligand reduces the conformational plasticity of the SARS virus pseudoknot | |
| Adams et al. | Structure activity relationships of αv integrin antagonists for pulmonary fibrosis by variation in aryl substituents | |
| Wolf | Predicting protein–ligand binding and unbinding kinetics with biased MD simulations and coarse-graining of dynamics: Current state and challenges | |
| Salamatova et al. | Hydrophobic collapse in N-methylacetamide–water mixtures | |
| Lavallée-Adam et al. | Discovery of cell compartment specific protein–protein interactions using affinity purification combined with tandem mass spectrometry | |
| Vogt et al. | From activity cliffs to activity ridges: informative data structures for SAR analysis | |
| Veselovsky et al. | Computer-aided design and discovery of protein–protein interaction inhibitors as agents for anti-HIV therapy | |
| Kontijevskis | Mapping of drug-like chemical universe with reduced complexity molecular frameworks | |
| Batista et al. | Assessment of molecular similarity from the analysis of randomly generated structural fragment populations | |
| Hiss et al. | Combinatorial chemistry by ant colony optimization | |
| Clark et al. | Grand canonical free-energy calculations of protein− ligand binding | |
| Coan et al. | Measurement and differentiation of ligand-induced calmodulin conformations by dual polarization interferometry | |
| Liu et al. | Using molecular fingerprint as descriptors in the QSPR study of lipophilicity | |
| Wu et al. | Quantitative validation and application of the photo-cross-linking selection for double-stranded DNA-encoded libraries | |
| Maciejewski et al. | Experimental design strategy: weak reinforcement leads to increased hit rates and enhanced chemical diversity |